Glutathione Modulates Activation-dependent Proliferation of Human Peripheral Blood Lymphocyte Populations Without Regulating Their Activated Function
Overview
Authors
Affiliations
L-Buthionine-(S,R)-sulfoximine (BSO) specifically depletes GSH synthesis by inactivating gamma-glutamylcysteine synthetase, whereas 2-ME augments intracellular GSH concentration. These reagents were used to examine GSH regulation of the proliferation and function of human PBL in response to IL-2 or OKT-3 mAb directed at the CD3 T cell Ag. 2-ME enhanced both IL-2-induced proliferation of PBL and CD3- large granular lymphocytes (LGL) and OKT-3 mAb-induced proliferation of CD3+ T cells. BSO partially suppressed activation-induced proliferation in CD3- LGL and CD3+ T cells and totally inhibited the positive co-proliferative regulation by 2-ME in these cells. By contrast, neither BSO nor 2-ME appeared to affect the activation-dependent differentiation of cytotoxic lymphocytes. The absence of effect of 2-ME or BSO on activation-induced PBL NK activity and T cell cytotoxic potential was supported by their negligible effect on the induction of two different markers of activated cytotoxic lymphocytes, namely pore-forming protein gene expression and benzoyloxycarbonyl-1-L-lysine thiobenzylester-esterase activity. BSO inhibition of CD3- LGL proliferation accounted for the inhibitory effects of BSO on both IFN-gamma production in IL-2-stimulated PBL cultures and IL-2-induced PBL lymphokine activated killer activity. The modulatory effects of 2-ME and BSO on lymphocyte proliferation regardless of phenotype (LGL vs T cell) or stimulation (IL-2, via CD3, lectin, etc.) and the functional differentiation of cytotoxic lymphocytes independent of proliferation suggests that these cells share a common site of GSH regulation close to or at the level of DNA synthesis.
Reconditioned monocytes are immunomodulatory and regulate inflammatory environment in sepsis.
Jain K, Mohan K, Roy G, Sinha P, Jayaraman V, Kiran Sci Rep. 2023; 13(1):14977.
PMID: 37696985 PMC: 10495550. DOI: 10.1038/s41598-023-42237-4.
Li X, Li Y, Yu Q, Qian P, Huang H, Lin Y J Leukoc Biol. 2021; 110(2):257-270.
PMID: 34075637 PMC: 8361984. DOI: 10.1002/JLB.1MR0421-597RR.
Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells.
Chakraborty P, Chatterjee S, Kesarwani P, Thyagarajan K, Iamsawat S, Dalheim A J Biol Chem. 2019; 294(23):9198-9212.
PMID: 30971427 PMC: 6556575. DOI: 10.1074/jbc.RA118.006753.
Gust K, Chaitankar V, Ghosh P, Wilbanks M, Chen X, Barker N BMC Genomics. 2018; 19(1):877.
PMID: 30518325 PMC: 6282355. DOI: 10.1186/s12864-018-5270-0.
Matta P, Sherrod S, Marasco C, Moore D, McLean J, Weitkamp J J Immunol. 2017; 199(9):3074-3085.
PMID: 28947540 PMC: 5659751. DOI: 10.4049/jimmunol.1601880.